Chiara Catania

769 total citations
28 papers, 401 citations indexed

About

Chiara Catania is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Chiara Catania has authored 28 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Neurology. Recurrent topics in Chiara Catania's work include Myasthenia Gravis and Thymoma (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Research Studies (6 papers). Chiara Catania is often cited by papers focused on Myasthenia Gravis and Thymoma (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Research Studies (6 papers). Chiara Catania collaborates with scholars based in Italy, United States and Belgium. Chiara Catania's co-authors include Tommaso De Pas, Fabio Conforti, Francesca Toffalorio, Gianluca Spitaleri, Cristina Noberasco, Angelo Delmonte, Giuseppe Viale, Laura Pala, Marco Colleoni and Aron Goldhirsch and has published in prestigious journals such as Cancer Cell, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Chiara Catania

26 papers receiving 398 citations

Peers

Chiara Catania
Audrey Gros France
Yanfen Feng China
Hiroshi Kaise Japan
Emma J. Groen Netherlands
T.M. Kim South Korea
Anna Felisiak-Gołąbek Poland
Megan Kruse United States
Stefania Kokkali Greece
Jozef Malysz United States
Kim McManus United States
Audrey Gros France
Chiara Catania
Citations per year, relative to Chiara Catania Chiara Catania (= 1×) peers Audrey Gros

Countries citing papers authored by Chiara Catania

Since Specialization
Citations

This map shows the geographic impact of Chiara Catania's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Catania with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Catania more than expected).

Fields of papers citing papers by Chiara Catania

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiara Catania. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Catania. The network helps show where Chiara Catania may publish in the future.

Co-authorship network of co-authors of Chiara Catania

This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Catania. A scholar is included among the top collaborators of Chiara Catania based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Catania. Chiara Catania is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pala, Laura, Eleonora Pagan, Tommaso De Pas, et al.. (2024). “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”. The Breast. 73. 103672–103672. 1 indexed citations
2.
Pala, Laura, Eleonora Pagan, Chiara Oriecuia, et al.. (2024). Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis. EClinicalMedicine. 73. 102681–102681. 5 indexed citations
3.
4.
Conforti, Fabio, Laura Pala, Tommaso De Pas, et al.. (2023). Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clinical Cancer Research. 30(6). 1093–1103. 1 indexed citations
5.
Pas, Tommaso De, Giovanna Rossi, Paola Bossi, et al.. (2023). Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review. Current Oncology. 30(3). 3494–3499. 4 indexed citations
6.
Conforti, Fabio, Laura Pala, Chiara Corti, et al.. (2023). High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. Lung Cancer. 176. 98–102. 1 indexed citations
7.
Pala, Laura, Tommaso De Pas, Chiara Catania, et al.. (2023). Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis. Seminars in Oncology. 50(6). 140–143. 1 indexed citations
8.
Catania, Chiara, Andrea Riccardo Filippi, Claudia Sangalli, et al.. (2023). New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group. Critical Reviews in Oncology/Hematology. 190. 104108–104108. 1 indexed citations
9.
Pala, Laura, Tommaso De Pas, Chiara Catania, et al.. (2022). Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell. 40(7). 695–700. 35 indexed citations
10.
Antonarelli, Gabriele, Chiara Corti, Paolo Andrea Zucali, et al.. (2022). Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group. European Journal of Cancer. 174. 31–36. 12 indexed citations
11.
Conforti, Fabio, Paolo Andrea Zucali, Laura Pala, et al.. (2022). Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. The Lancet Oncology. 23(10). 1287–1296. 39 indexed citations
12.
13.
Repetto, Matteo, Fabio Conforti, Mariarosaria Calvello, et al.. (2021). Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European Journal of Cancer. 153. 162–167. 9 indexed citations
14.
Conforti, Fabio, Paolo Tarantino, Pamela Trillo Aliaga, et al.. (2020). Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews. 92. 102133–102133. 5 indexed citations
15.
Toffalorio, Francesca, Filippo de Marinis, Fabio Conforti, et al.. (2015). Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors. Journal of Thoracic Oncology. 10(2). 392–396. 4 indexed citations
16.
Spitaleri, Gianluca, Antonio Toesca, Edoardo Botteri, et al.. (2013). Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Critical Reviews in Oncology/Hematology. 88(2). 427–436. 141 indexed citations
17.
Lazzari, Chiara, Gianluca Spitaleri, Chiara Catania, et al.. (2013). Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options. Critical Reviews in Oncology/Hematology. 89(3). 358–365. 23 indexed citations
18.
Conforti, Fabio, Chiara Catania, Francesca Toffalorio, et al.. (2013). EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer. 81(3). 440–444. 34 indexed citations
19.
Catania, Chiara, Tiziana Ascione, Laura Adamoli, et al.. (2007). Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. Breast Cancer Research and Treatment. 106(1). 97–103. 7 indexed citations
20.
Nolè, Franco, Elisabetta Munzone, Mario Mandalà, et al.. (2001). Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. Annals of Oncology. 12(1). 95–100. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Audrey Gros Breakdown of academic impact, for papers by Yanfen Feng Breakdown of academic impact, for papers by Hiroshi Kaise Breakdown of academic impact, for papers by Emma J. Groen Breakdown of academic impact, for papers by T.M. Kim Breakdown of academic impact, for papers by Anna Felisiak-Gołąbek Breakdown of academic impact, for papers by Megan Kruse Breakdown of academic impact, for papers by Stefania Kokkali Breakdown of academic impact, for papers by Jozef Malysz Breakdown of academic impact, for papers by Kim McManus
Rankless by CCL
2026